Adagene Presents Clinical Data from NEObody™ Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting

NEXT STORY
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
PREV STORY
Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

author_avatar
NASDAQ Market News

Skylight Health to Provide a Discount Drug Card Program to its Expanding Subscription Offering for Uninsured Americans

author_avatar
NASDAQ Market News

GeneSight® Psychotropic Test Demonstrated Substantial Cost Savings for Payers in New Study Published in Clinical Therapeutics

SALT LAKE CITY, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary ...

author_avatar
NASDAQ Market News